May 2024 SOCRA Source Journal - Journal - Page 51
References
Althuis, M. D., Fergenbaum, J. H., Garcia-Closas, M., Brinton, L. A., Madigan, M. P. and Sherman,
M. E. (2004) ‘Etiology of hormone receptor–de昀椀ned breast cancer: a systematic review of the literature’,
Cancer Epidemiology and Prevention Biomarkers, 13(10), 1558-1568.
Anders, C. K. and Carey, L. A. (2009) ‘Biology, metastatic patterns, and treatment of patients with
triple-negative breast cancer’, Clinical Breast Cancer, 9, S73-S81.
Bae, S. Y., Lee, S. K., Koo, M. Y., Hur, S. M., Choi, M.-Y., Cho, D. H., Kim, S., Choe, J.-H., Lee, J. E. and
Kim, J.-H. (2011) ‘The prognoses of metaplastic breast cancer patients compared to those of triple-negative
breast cancer patients’, Breast Cancer Research and Treatment, 126(2), 471-478.
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C.,
O’Shaughnessy, J., Kalinsky, K. and Guarino, M. (2017) ‘Ef昀椀cacy and safety of anti-Trop-2 antibody drug
conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative
breast cancer’, Journal of Clinical Oncology, 35(19), 2141.
Birrell, S. N., Butler, L. M., Harris, J. M., Buchanan, G. and Tilley, W. D. (2007) ‘Disruption of androgen
receptor signaling by synthetic progestins may increase risk of developing breast cancer’,
The FASEB Journal, 21(10), 2285-2293.
Buess, M., Nuyten, D. S., Hastie, T., Nielsen, T., Pesich, R. and Brown, P. O. (2007) ‘Characterization of
heterotypic interaction effects in vitro to deconvolute global gene expression pro昀椀les in cancer’,
Genome Biology, 8(9), R191.
Buettner, R., Mora, L. B. and Jove, R. (2002) ‘Activated STAT signaling in human tumors provides
novel molecular targets for therapeutic intervention’, Clinical Cancer Research, 8(4), 945-954.
Chen, L., Li, C. I., Tang, M.-T. C., Porter, P., Hill, D. A., Wiggins, C. L. and Cook, L. S. (2016) ‘Reproductive
factors and risk of luminal, HER2-overexpressing and triple negative breast cancer among multiethnic women’,
Cancer Epidemiology and Prevention Biomarkers, cebp. 1104.2015.
Comen, E. A. and Robson, M. (2010) ‘Inhibition of poly (ADP)-ribose polymerase as a therapeutic strategy for
breast cancer’, Oncology, 24(1), 55.
Darnell, J. E. (1997) ‘STATs and gene regulation’, Science, 277(5332), 1630-1635.
de Prati, A. C., Ciampa, A. R., Cavalieri, E., Zaf昀椀ni, R., Darra, E., Menegazzi, M., Suzuki, H. and Mariotto, S.
(2005) ‘STAT1 as a new molecular target of anti-in昀氀ammatory treatment’, Current Medicinal Chemistry, 12(16),
1819-1828.
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E.,
Sun, P. and Narod, S. A. (2007) ‘Triple-negative breast cancer: clinical features and patterns of recurrence’,
Clinical Cancer Research, 13(15), 4429-4434.
Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L. and Malone, K. E. (2009) ‘Risk
factors for triple-negative breast cancer in women under the age of 45 years’, Cancer Epidemiology and
Prevention Biomarkers, 18(4), 1157-1166.
Foulkes, W. D., Smith, I. E. and Reis-Filho, J. S. (2010) ‘Triple-negative breast cancer’, New England Journal of
Medicine, 363(20), 1938-1948.
Garrido-Castro, A. C., Lin, N. U. and Polyak, K. (2019) ‘Insights into Molecular Classi昀椀cations of Triple-Negative
Breast Cancer: Improving Patient Selection for Treatment’, Cancer Discovery, 9(2), 176-198.
SOCRA SOURCE © May 2024
51